Mr. Kindler has served as a Board member since November 2011. He is the Chief Executive Officer of Centrexion Corporation, a privately held clinical stage biopharmaceutical company; an Operating Partner at Artis Ventures, a leading venture capital firm; and a managing director at Starboard Capital Partners, a private equity firm. Mr. Kindler was also a Venture Partner at Lux Capital, a leading venture capital firm, from January 2017 to January 2020. Mr. Kindler was Chief Executive Officer and Chairman of the Board of Pfizer, Inc. (NYSE:PFE), a pharmaceutical company, from 2006 until his retirement in December 2010. He joined Pfizer in 2002 as Executive Vice President and General Counsel and assumed positions of increasing responsibility until being named Chief Executive Officer in 2006. Prior to joining Pfizer, he was Chairman of Boston Market Corporation from 2000 to 2001 and President of the Partner Brands group of McDonald’s Corporation during 2001.
In addition to serving on Precigen’s Board, Mr. Kindler currently serves on the boards of PPD, Inc. (Nasdaq: PPD), a provider of drug development services, Siga Technologies, Inc. (Nasdaq:SIGA), a developer of novel antiviral therapeutics, vTV Therapeutics (Nasdaq:VTVT), a development-stage biopharmaceutical company, and Perrigo Company (NYSE:PRGO), a healthcare company. Mr. Kindler also serves as a board member for a number of privately held companies and for several civic, charitable, educational and other organizations. He also serves as Chairman of the GLG Institute. Previously, Mr. Kindler served on the board of Chipotle Mexican Grill, Inc. (NYSE:CMG), a chain of Mexican restaurants, from 2012 to 2014. Mr. Kindler received a BA. from Tufts University and a JD from Harvard Law School.
What is Jeffrey B. Kindler's net worth?
The estimated net worth of Jeffrey B. Kindler is at least $114.23 thousand as of August 26th, 2026. Mr. Kindler owns 17,100 shares of Precigen stock worth more than $114,228 as of September 11th. This net worth estimate does not reflect any other assets that Mr. Kindler may own. Learn More about Jeffrey B. Kindler's net worth.
How do I contact Jeffrey B. Kindler?
Has Jeffrey B. Kindler been buying or selling shares of Precigen?
During the last quarter, Jeffrey B. Kindler has sold $1,376,400.00 in shares of Precigen stock. Most recently, Jeffrey B. Kindler sold 185,000 shares of the business's stock in a transaction on Wednesday, August 26th. The shares were sold at an average price of $7.44, for a transaction totalling $1,376,400.00. Following the completion of the sale, the director now directly owns 17,100 shares of the company's stock, valued at $127,224. Learn More on Jeffrey B. Kindler's trading history.
Who are Precigen's active insiders?
Precigen's insider roster includes Nancy Agee (Director), Steven Frank (Director), Jeffrey Kindler (Director), Randal Kirk (Director), Donald Lehr (Insider), David Obstler (CFO), Jeffrey Perez (SVP), Helen Sabzevari (CEO), Rutul Shah (COO), and Harry Thomasian, Jr. (CFO). Learn More on Precigen's active insiders.
Are insiders buying or selling shares of Precigen?
In the last year, Precigen insiders bought shares 4 times. They purchased a total of 16,627 shares worth more than $71,477.05. In the last year, insiders at the biotechnology company sold shares 24 times. They sold a total of 17,847,628 shares worth more than $68,637,124.59. The most recent insider tranaction occured on August, 26th when Director
Jeffrey B. Kindler sold 185,000 shares worth more than $1,376,400.00. Insiders at Precigen own 41.4% of the company.
Learn More about insider trades at Precigen. Information on this page was last updated on 8/26/2026.
